[Recorded Nov. 5, 2020]

The COVID-19 pandemic has highlighted a needs for non-invasive, remote approaches to patient care. 

Learn how companies like Neuroelectrics are working to bring non-invasive brain stimulation into the home. In May, 2020, Neuroelectrics received FDA approval for a clinical trial of at-home brain stimulation therapy via telemedicine for patients with Major Depressive Disorder (MDD). An additional trial with Boston Children’s Hospital (IDE G160208) is already underway, studying the therapy for treatment-resistant epilepsy.

This nonaccredited educational webinar is provided for information only. 

[Recorded Oct. 8, 2020]

What does it take to turn a big idea into a new therapy?
This engaging conversation with Eric Grigsby, MD, MBA, and David Caraway, MD PhD, explores the phases of breakthrough innovation and therapeutic development. 

This nonaccredited educational webinar is provided for information only.

[Recorded Sept. 10, 2020]

A deep dive into how a hypothesis can change the way we think about SCS therapies and optimizing outcomes.
Dr. Vallejo unpacks the questions necessary to build a truer understanding of the effects of SCS and how the answers to these questions influence patient outcomes.

This nonaccredited educational webinar is provided for information only.

Recent Publications:

• Vallejo, R., Kelley, C. A., Gupta, A., Smith, W. J., Vallejo, A., & Cedeño, D. L. (2020). Modulation of neuroglial interactions using differential target multiplexed spinal cord stimulation in an animal model of neuropathic pain. Molecular Pain, 16, 1744806920918057.
• Vallejo, R., & Cedeño, D. L. (2020). The quest for neurobiological mechanisms of electrical stimulation of the spinal cord to reduce chronic neuropathic pain. Future Medicine (2020): 139-142.
• Fishman, M. A., Calodney, A., Kim, P., Slezak, J., Benyamin, R., Rehman, A., ... & Yu, C. (2020). Prospective, Multicenter Feasibility Study to Evaluate Differential Target Multiplexed Spinal Cord Stimulation Programming in Subjects With Chronic Intractable Back Pain With or Without Leg Pain. Pain Practice.

[Recorded July 16, 2020]

Rheumatoid arthritis (RA) is an autoimmune disease which leads to permanent joint destruction and accelerated mortality requiring lifelong immunosuppressive therapies. Activation of neuroimmune reflexes by vagal nerve stimulation (VNS) reduced disease activity in a proof-of-concept study in RA.

This nonaccredited educational webinar is provided for information only.

[Recorded July 2, 2020]

Drs. Eric Grigsby, and Lawrence Poree held an in-depth conversation on equity and inclusion in pain management.

The conversation elucidates:

• Identifying and stopping patient bias
• Breaking down bias in the workplace

This nonaccredited educational webinar is provided for information only.

Additional resources:

• HHS Action Plan to Reduce Racial and Ethnic Health Disparities
• A Practical Guide to Implementing the National CLAS Standards: For Racial, Ethnic and Linguistic Minorities, People with Disabilities and Sexual and Gender Minorities
• Reducing Racial Health Care Disparities: A Social Psychological Analysis

[Recorded May 28, 2020]

Learn:

• The potential of non-invasive Vagus Nerve Stimulation (nVNS) therapy to address COVID-19 induced cytokine storm.
• Preliminary observations and a strong scientific foundation suggest that nVNS might provide clinical benefits in patients with COVID‐19 via multiple mechanisms.

This nonaccredited educational webinar is provided for information only.

[Recorded May 7, 2020]

Preparing Your Re-entry Plan

Mapping the Future of Pain Procedures with Neuromodulation and COVID-19

Eric J. Grigsby, MD, MBA and NANS Board Member, Stephanie G. Vanterpool, MD, MBA review exploring NANS’ Neuromodulation Device Algorithm for COVID-19.

Learn:

• How to classify the management of currently implanted neuromodulation devices as “elective” or “essential”
• Considerations for pump management during the pandemic
• Stages for re-entry: testing, tracing, and community health
• How to get back to a “new normal” once we resume doing procedures…. i.e. It won’t be business as usual

This guidance refers to the management of currently implanted neuromodulation devices. With rare exception, implantation of new devices is considered elective in the current COVID-19 environment.

This nonaccredited educational webinar is provided for information only.